Down Syndrome

Non-invasive maternal serum screening test: This detection is based on a multi-analyte assay utilizing mass spectrometry, and the discoveries resulted in awards to ProteoGenix of NIH Phase-I and Phase-II SBIR grants. Furthermore, the Society for Maternal Fetal Medicine recognized the company’s scientific presentation at their annual meeting with its Best Research Award. With approximately 2.6 million commercial tests annually in the US, the potential market for a more accurate diagnostic methodology is well established.

© Copyright 2005-2007. All rights reserved.

Proteogenix